학제간연구 | Interdisciplinary Studies in Gambling | 跨学科研究
- date : 2015-05-20 01:10|hit : 1888
-
- Article] Valuing health states for use in cost-effectiveness analysis
-
DocNo of ILP: 4007
Doc. Type: Article
Title: Valuing health states for use in cost-effectiveness analysis
Authors: Brazier, J
Full Name of Authors: Brazier, John
Keywords by Author:
Keywords Plus: VISUAL ANALOG SCALE; QUALITY-OF-LIFE; UTILITY ANALYSIS; STANDARD GAMBLE; VALUATION; MULTIATTRIBUTE; SYSTEM; VALUES; INDEX; EUROQOL
Abstract: This article reviews the general issues in valuing health states for use in cost-effectiveness analysis and the specific issues considered by the National Institute for Health and Clinical Excellence (NICE) in its recent review of the methods of technology appraisal. The general issues are how to describe health, how to value health and who should provide the values for health. The specific issues considered by NICE included whether and what should be the reference-case instrument, what to do when there are no data using the reference-case measure, what to do when the reference-case measure is not suitable and how to judge when it is not suitable, how to review and synthesize data, and how to incorporate health-state utility values into cost-effectiveness models.
Cate of OECD: Economics and business
Year of Publication: 2008
Business Area: gamble
Detail Business: gamble
Country: New Zealand
Study Area:
Name of Journal: PHARMACOECONOMICS
Language: English
Country of Authors: Univ Sheffield, Sch Hlth & Related Res, NICE Decis Support Unit, Sheffield, S Yorkshire, England
Press Adress: Brazier, J (reprint author), Univ Sheffield, Sch Hlth & Related Res, NICE Decis Support Unit, 30 Regent St, Sheffield, S Yorkshire, England.
Email Address: j.e.brazier@shef.ac.uk
Citaion:
Funding: NICE
Lists of Citation: ARA R, VALUE HLTH; Barton Garry R, 2004, Appl Health Econ Health Policy, V3, P103, DOI 10.2165/00148365-200403020-00006; Beattie J, 1998, J RISK UNCERTAINTY, V17, P5, DOI 10.1023/A:1007711416843; BLEICHRODT H, 2002, HEALTH ECON, V11, P1447; Brazier J, 2007, MEASURING VALUING HL; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier J, 2007, REV METHODS MAPPING; Brazier J, 2008, MED DECIS MAKING, V28, P113, DOI 10.1177/0272989X07301820; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; CLAXTON C, 2008, PHARMACOECONOMICS, V26, P781; COAST J, 1992, BRIT MED J, V305, P87; Dolan P, 2008, ECON J, V118, P215; Dolan P, 1997, SOC SCI MED, V44, P1519, DOI 10.1016/S0277-9536(96)00271-7; Dolan P, 2000, HDB HLTH EC, V1; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Dolan P., 2002, DISTRIBUTING HLTH CA; DONALDSON C, 1997, SOC SCI MED, V44, P285; Drummond MF, 2005, METHODS EC EVALUATIO; Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072; Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006; FITZPATRICK R, 2006, STRUCTURED REV PROMS; GAFNI A, 1993, J HEALTH ECON, V12, P325, DOI 10.1016/0167-6296(93)90015-7; Gold M, 1996, COST EFFECTIVENESS H; HALL J, 1992, SOC SCI MED, V34, P993, DOI 10.1016/0277-9536(92)90130-I; *HM TREAS, 2004, GREEN BOOK APPR EV C; International Society for Pharmacoeconomics and Outcomes Research, PHARM GUID WORLD; Kaltenthaler E, 2002, Health Technol Assess, V6, P1; KARNON J, 2005, CURR MED RES OPIN, V21, P91; Marra CA, 2005, SOC SCI MED, V60, P1571, DOI 10.1016/j.socscimed.2004.08.034; McCabe C, 2005, HEALTH ECON, V14, P231, DOI 10.1002/hec.925; McCabe C, 2006, J HEALTH ECON, V25, P418, DOI 10.1016/j.jhealeco.2005.07.008; *NAT I HLTH CLIN E, 2008, REV GUID METH TECHN; *NAT I HLTH CLIN E, 2007, SOC VAL JUDG PRINC D; National Institute for Health and Clinical Excellence (NICE), 2004, GUID METH TECHN APPR; NORD E, 1995, MED DECIS MAKING, V15, P201, DOI 10.1177/0272989X9501500302; Olsen JA, 2001, HEALTH ECON, V10, P39, DOI 10.1002/1099-1050(200101)10:1<39::AID-HEC563>3.0.CO;2-E; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; RICHARDSON J, 1994, SOC SCI MED, V39, P7, DOI 10.1016/0277-9536(94)90162-7; Salomon JA, 2003, POPUL HEALTH METR, V1, P12, DOI 10.1186/1478-7954-1-12; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; STEVENS K, 2008, HEDS DISCUSSION PAPE, V804; Stevens KJ, 2006, HEALTH ECON, V15, P527, DOI 10.1002/hec.1076; Stevenson MD, 2005, J OPER RES SOC, V56, P214, DOI 10.1057/palgrave.jors.2601903; Sugar CA, 1998, HEALTH SERV RES, V33, P911; Tengs TO, 2000, MED CARE, V38, P583, DOI 10.1097/00005650-200006000-00004; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Ubel PA, 2003, QUAL LIFE RES, V12, P599, DOI 10.1023/A:1025119931010; US Department of Health and Human Services, 2006, GUID IND PAT REP OUT; YANG Y, VALUE HLTH IN PRESS
Number of Citaion: 50
Publication: ADIS INT LTD
City of Publication: AUCKLAND
Address of Publication: 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND
ISSN: 1170-7690
29-Character Source Abbreviation: PHARMACOECONOMICS
ISO Source Abbreviation: Pharmacoeconomics
Volume: 26
Version: 9
Start of File: 769
End of File: 779
DOI: 10.2165/00019053-200826090-00007
Number of Pages: 11
Web of Science Category: Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy
Subject Category: Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy
Document Delivery Number: 356RC
Unique Article Identifier: WOS:000259794300007
- reply : 0
-
- list
-
- prev
- next